Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin’s Lymphoma
This study is currently recruiting patients.
Sponsored by: | European Organization for Research and Treatment of Cancer |
---|---|
Information provided by: | National Cancer Institute (NCI) |
Purpose
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, prednisone, and gemcitabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more cancer cells.
PURPOSE: Randomized phase II trial to compare the effectiveness of combining cyclophosphamide, doxorubicin, vincristine, and prednisone with or without gemcitabine in treating patients who have previously untreated aggressive stage II, stage III, or stage IV non-Hodgkin's lymphoma.
Condition | Treatment or Intervention | Phase |
---|---|---|
adult diffuse large cell lymphoma anaplastic large cell lymphoma angioimmunoblastic T-cell lymphoma grade 3 follicular lymphoma |
Drug: cyclophosphamide Drug: doxorubicin Drug: gemcitabine Drug: prednisone Drug: vincristine Procedure: chemotherapy |
Phase II |
MedlinePlus related topics: Cancer; Cancer Alternative Therapy; Immune System and Disorders; Lymphatic Diseases; Lymphoma
Study Type: Interventional
Study Design: Treatment
Official Title: Phase II Randomized Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With Versus Without Gemcitabine in Patients With Previously Untreated Aggressive Non-Hodgkin’s Lymphoma
OBJECTIVES: Primary
Secondary
OUTLINE: This is an open-label, randomized, multicenter study. Patients are stratified according to participating center, International Prognostic Index score (0-2 vs 3-5), and histology (B cell vs T cell). Patients are randomized to 1 of 2 treatment arms.
Patients are followed every 3 months for 3 years, every 6 months for 2 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 76-82 patients (38-41 per treatment arm) will be accrued for this study within 2 years.
Eligibility
Ages Eligible for Study: 18 Years - 70 Years, Genders Eligible for Study: Both
Criteria
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS: Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Cardiovascular
Pulmonary
Other
PRIOR CONCURRENT THERAPY: Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
Location and Contact Information
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |